In the News
Press Release

10/01/2024

Chiesi Global Rare Diseases Announces Publication of Results from Phase 3 BALANCE Study in Fabry Disease

PARMA, January 10, 2024 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced the publication of data from the Phase 3 BALANCE study that evaluated...

Read More

Press release

05/05/2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease.

PARMA, Italy, BOSTON, and CARMIEL, Israel, May 05, 2023 - Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through...

Read More
VIEW MORE
VIEW MORE
VIEW MORE

Join our rare community

Join us online and take part in the global conversation about rare diseases.

Netherlands

Belgium

Learn More about Chiesi Global Rare Diseases - Benelux

Products

Discover treatments that are helping to change the rare disease landscape.

Read More

Pipeline

Explore rare disease therapies under development.

Read More
For Healthcare Professionals

For Healthcare
Professionals

From research to results, see how we’re committed to helping you help your patients.

Read More
About US

About 
Us

Learn more about who we are and why Chiesi Global Rare Disease - Benelux cares about improving the lives of people with rare diseases.

Read More